Triple

T2430989
Position Surface form Disambiguated ID Type / Status
Subject NIDA Notes E52843 entity
Predicate publisher P29 FINISHED
Object NIDA E9512 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: NIDA | Statement: [NIDA Notes, publisher, NIDA]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: NIDA
Context triple: [NIDA Notes, publisher, NIDA]
  • A. NIDA International Program
    NIDA International Program is a global initiative of the U.S. National Institute on Drug Abuse that fosters international collaboration in drug abuse research, training, and policy.
  • B. National Institute on Drug Abuse chosen
    The National Institute on Drug Abuse is a U.S. federal research agency that leads scientific study on drug use, addiction, and their health impacts to inform prevention, treatment, and policy.
  • C. NIDA Drug Supply Program
    The NIDA Drug Supply Program is a U.S. government initiative that provides researchers with controlled substances and related materials to support scientific studies on drug abuse and addiction.
  • D. NIDA Notes
    NIDA Notes is a publication of the National Institute on Drug Abuse that reports on research findings and developments related to drug use, addiction, and their prevention and treatment.
  • E. NIDA Division of Therapeutics and Medical Consequences
    The NIDA Division of Therapeutics and Medical Consequences is a branch of the National Institute on Drug Abuse that oversees research and development of treatments and medical interventions related to substance use and its health impacts.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ab4959bcc0819083246f9fb10439e3 completed March 6, 2026, 9:38 p.m.
NER Named-entity recognition batch_69abc9c767a88190b31cbccdce8e8982 completed March 7, 2026, 6:46 a.m.
NED1 Entity disambiguation (via context triple) batch_69af17864e9881909b32b70d55028016 completed March 9, 2026, 6:55 p.m.
Created at: March 6, 2026, 9:43 p.m.